NCT06215612Not yet recruiting
ctDNA and MRI Parameters in Head and Neck Cancer
ctDNA and MR Imaging Parameters as Possible Biomarkers in Primary Radiochemotherapy of Head and Neck Squamous Cell Carcinomas
Source: ClinicalTrials.gov · Last updated 22 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 29 Dec 2023
- Start date
- Feb 2024
- Primary completion date
- Feb 2027
- Lead sponsor
- Franziska Eckert
- Diseases
- Head and neck cancer
- NCT number
- NCT06215612
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Feb 2024 to the primary completion date, Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Palliative therapy intent
Other
- Not MR eligible
Who the study is looking for
- Squamous cell carcinoma head and neck
- Planned primary platinum based radiochemotherapy
- ECOG 0-2
Age in the registry: 19 years to 100 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.